Search research articles
Contact Us
Filters
Showing results (81-90 of 93) with videos related to
Page
of 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
March 16, 2013
Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group
Andreas du Bois, Nina Ewald-Riegler, Nikolaus de Gregorio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 13, 2013
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study
Paul Sabbatini, Philipp Harter, Giovanni Scambia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2022
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
Jacobus Pfisterer, Florence Joly, Gunnar Kristensen, et al.
Geburtshilfe Und Frauenheilkunde
|
December 9, 2020
Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense?
Linn Woelber, Mareike Bommert, Katharina Prieske, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 13, 2016
Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study
Linn Woelber, Lis-Femke Griebel, Christine Eulenburg, et al.
Journal of Medical Genetics
|
April 14, 2019
Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883)
Jan Hauke, Eric Hahnen, Stephanie Schneider, et al.
Biorxiv : the Preprint Server for Biology
|
November 1, 2024
ZNFX1 is a Novel Master Regulator in Epigenetically-induced Pathogen Mimicry and Inflammasome Signaling in Cancer
Lora Stojanovic, Rachel Abbotts, Kaushlendra Tripathi, et al.
The Lancet. Oncology
|
April 20, 2020
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, et al.
Plos One
|
October 21, 2017
Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)
Philipp Harter, Jan Hauke, Florian Heitz, et al.
Cancer Research
|
January 13, 2025
ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer
Lora Stojanovic, Rachel Abbotts, Kaushelendra Tripathi, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 93) with videos related to
Sort By:
Page
of 10
European Journal of Cancer (Oxford, England : 1990)
|
March 16, 2013
Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group
Andreas du Bois, Nina Ewald-Riegler, Nikolaus de Gregorio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 13, 2013
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study
Paul Sabbatini, Philipp Harter, Giovanni Scambia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2022
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
Jacobus Pfisterer, Florence Joly, Gunnar Kristensen, et al.
Geburtshilfe Und Frauenheilkunde
|
December 9, 2020
Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense?
Linn Woelber, Mareike Bommert, Katharina Prieske, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 13, 2016
Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study
Linn Woelber, Lis-Femke Griebel, Christine Eulenburg, et al.
Journal of Medical Genetics
|
April 14, 2019
Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883)
Jan Hauke, Eric Hahnen, Stephanie Schneider, et al.
Biorxiv : the Preprint Server for Biology
|
November 1, 2024
ZNFX1 is a Novel Master Regulator in Epigenetically-induced Pathogen Mimicry and Inflammasome Signaling in Cancer
Lora Stojanovic, Rachel Abbotts, Kaushlendra Tripathi, et al.
The Lancet. Oncology
|
April 20, 2020
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, et al.
Plos One
|
October 21, 2017
Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)
Philipp Harter, Jan Hauke, Florian Heitz, et al.
Cancer Research
|
January 13, 2025
ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer
Lora Stojanovic, Rachel Abbotts, Kaushelendra Tripathi, et al.
Page
of 10